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and clinical utility for diagnosis and
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Abstract
The formation of neutrophil extracellular traps (NETs), known as NETosis, was first observed as a novel immune
response to bacterial infection, but has since been found to occur abnormally in a variety of other inflammatory
disease states including cancer. Breast cancer is the most commonly diagnosed malignancy in women. In breast
cancer, NETosis has been linked to increased disease progression, metastasis, and complications such as venous
thromboembolism. NET-targeted therapies have shown success in preclinical cancer models and may prove
valuable clinical targets in slowing or halting tumor progression in breast cancer patients. We will briefly outline the
mechanisms by which NETs may form in the tumor microenvironment and circulation, including the crosstalk
between neutrophils, tumor cells, endothelial cells, and platelets as well as the role of cancer-associated
extracellular vesicles in modulating neutrophil behavior and NET extrusion. The prognostic implications of cancer-
associated NETosis will be explored in addition to development of novel therapeutics aimed at targeting NET
interactions to improve outcomes in patients with breast cancer.
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Background
Neutrophils are the most abundant type of white blood cells
in the circulation and are often considered the frontline de-
fenders in innate immunity [1]. These leukocytes were only
recently observed to be capable of a novel immune response
in which they expel their DNA and intracellular contents in
a web-like structure known as a neutrophil extracellular trap
(NET). NETs form when activated neutrophils release DNA,
histones, and granular content, exposing antimicrobial and
proinflammatory proteins [2]. NETosis occurs as specific
proteases are translocated into the neutrophil nucleus,
which causes their chromatin to decondense through citrul-
lination. These loosely networked strands are then ultim-
ately expelled from the cell, rupturing it or leaving the
membrane intact. Subsequent membrane integrity depends
on the nature of the stimulus provoking NETosis [3]. NETs
were first observed as a response to bacterial infection, as
histones, and released neutrophil granular content have anti-
microbial properties and the fibrous NET structure can
physically entrap and kill bacteria [2]. However, NETs have
since been associated with sterile inflammation in a variety
of disease states, including gout, cystic fibrosis, type 1 dia-
betes, rheumatoid arthritis, preeclampsia, and others [4–9].
NETs have also been associated with tumor cell proliferation
and metastasis [10–16], cancer-related thrombosis [17–21],
and primary tumor growth [22, 23].
In this review, we will focus on the role of NETs primar-
ily in breast cancer. Globally, breast cancer accounted for
around 11.6% of new cancer diagnoses in 2018 and was
estimated to be responsible for more than 6% of all cancer
deaths [24]. Current evidence suggests that NET produc-
tion in cancer involves a complex interplay between a
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variety of cells and blood components, including platelets,
leukocytes, pioneering metastatic tumor cells, and the pri-
mary tumor site itself [10, 19, 21, 25–28]. NETs promote
the progression of an inflammatory microenvironment,
which develops a positive feedback loop: NETs released
into the circulation damage endothelial cells, which pro-
motes further inflammation, causing activation of platelets
and other neutrophils which can cause further NET re-
lease. Platelet activation caused by NETs can also promote
several negative outcomes associated with late-stage meta-
static breast cancer, including venous thromboembolism
(VTE) [29]. This review will discuss both established and
potential stimuli that promote oncogenic NETosis, both
on a molecular level and in terms of interactions between
neutrophils, other blood components in cancer-affected
organisms, and tumor cells themselves. We will also dis-
cuss the consequences of NETosis, especially as it relates
to breast cancer progression. Finally, the use of NETs as
potential diagnostic biomarkers and/or clinical therapeutic
targets in cancer will be discussed.
Cellular and molecular stimulants of NETosis
Pro-NETotic stimuli and neutrophil components required for
NETosis
Several potential pro-NETotic stimuli relevant to cancer
progression are listed in Table 1. The most classical and
potent stimuli provoking NET formation are products of
bacterial infection, such as lipopolysaccharide (LPS), or
non-endogenous inflammatory pathway activators such
as phorbol 12-myristate 13-acetate (PMA) [2]. LPS and
PMA promote NETosis through production of reactive
oxygen species (ROS) in which oxygen is transformed
into damaging superoxide radicals and secondary oxi-
dants. ROS are key to cancer and inflammatory signaling
as well as neutrophil behavior modulation [45, 46]. The
inflammatory state associated with cancer also may pro-
voke systemic oxidative stress. The presence of higher
levels of NETosis observed in many cancers may (at least
partially) be attributed directly to tumor cells, as well as
indirectly via ROS generation by other cells and granules
activated by downstream effects of tumor released fac-
tors. It has been shown that PMA provokes NETosis
through activation of p38 MAPK via NADPH oxidase
generation of ROS [32]; thus, endogenous stimulants
may follow similar pathways. Interestingly, p38 activa-
tion has also been shown to promote breast cancer cell
survival and proliferation and has been linked to poor
clinical outcomes in humans [47, 48].
Although NADPH oxidase inhibition has been shown
to prevent NETosis, not all NETosis appears to be ROS-
dependent. In fact, the mechanism of NET release ap-
pears to be influenced by the presence or absence of
ROS [3, 49]. ROS-dependent NETosis results in neutro-
phil cell death, known as lytic NETosis, wherein the cell
Table 1 Key NET stimuli involved in cancer progression. References are annotated to indicate whether NETotic effect has been
shown in human (H) neutrophils, mouse (M) neutrophils, or both (HM)
Stimulus/model: Relevance to cancer progression: Origin:
LPS [2, 30, 31]HM May simulate response to infection; repeated
intranasal dosage in mice activated dormant
cancer cells and enhanced metastatic proliferation
Gram-negative bacteria
PMA [2, 32]H N/A Synthetic/pharmaceutical
Platelet-activating factor [19]M Promotes tumor cell proliferation, neovascularization,
and immunosuppressive phenotype
Leukocyte, platelet, and endothelial secretion
in inflammation
HMGB1 [14, 25, 33]HM Associates with existing NETs; role in platelet and
neutrophil activation; synergizes with LPS and thus
may exacerbate response to infection
Leukocyte and platelet secretion in inflammation;
expressed in some tumors; released during
cell death
IL-8 [5, 34, 35]H Drives neutrophilia; positive correlation with poor
outcome in women with breast cancer
Expressed in some tumors; released from
activated endothelial cells
G-CSF [19, 36, 37]M Drives neutrophilia; positive correlation with
metastasis; potentiates extracellular vesicle driven
NETosis
Expressed in some tumors
PAD4 [38–40]HM Catalyzes histone citrullination; inhibition prevents
NETosis in most circumstances
Neutrophils; expressed in some tumors
P-selectin [41]M Facilitates neutrophil motility; drives
platelet-neutrophil aggregation
Endothelial cells; platelets
TF [42–44]H Activates platelets which activate neutrophils
and causes NETosis, potentially through multiple
pathways
Secreted during NETosis; expressed in some tumors;
contained in tumor EVs
Tumor EVs [21]M May influence neutrophil behavior once taken up;
contain inflammatory cytokines and are vital to
oncogenic signaling; prothrombotic
Released from tumor cells
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membrane lyses and decondensed chromatin forms
NETs. In contrast, ROS-independent NETosis is much
more rapid, taking minutes as opposed to hours. The
nuclear envelope disintegrates, and the decondensed
chromatin is extruded as NETs via vesicular transport;
the preserved integrity of the plasma membrane allows
the anuclear neutrophil to survive and retain functional-
ity. Though mechanisms leading to each process and
their distinct effects remain unclear, vital NETosis ap-
pears more commonly in the context of infectious dis-
ease, whereas lytic NETosis is observed in sterile injury
[7, 49]. Further investigation of whether NETosis is vital,
lytic, or both in the context of cancer is needed.
Regardless of the stimuli present, certain factors within
the neutrophil have been shown to be critical to NET re-
lease. These include protein arginine deiminase 4 (PAD4),
neutrophil elastase (NE), and myeloperoxidase (MPO).
PAD4 is a calcium-dependent enzyme localized within the
nucleus, cytoplasm, and secretory granules of neutrophils.
Inside the nuclear envelope, PAD4 catalyzes hypercitrulli-
nation of histones H3, H2A, and H4, which contributes to
chromatin decondensation [50]. Histone citrullination is
widely considered to be characteristic of NETosis and fluor-
escent antibodies against citrullinated histones are often
used to identify released NETs [38, 51]. Selective inhibition
of PAD4 has been shown to abrogate NETosis in response
to PMA and a wide variety of physiological stimuli, sup-
porting the critical role of PAD4 in NET release [39]. How-
ever, NETosis has been observed in the absence of either or
both histone citrullination and PAD4 activation, which sug-
gests additional mechanisms for NET release. Jorch and
Kubes’s [7] recent review proposes that other neutrophil
granule components, such as NE and MPO, may be suffi-
cient for PAD-independent NETosis. NE is capable of
cleaving histones within the nuclear envelope to begin
chromatin decondensation. Although MPO independently
also appears to have a modest effect on decondensation, its
contribution to altering the chromatin structure increases
in the presence of NE. MPO binds to DNA and catalyzes
oxidative reactions, which promotes the relocation of NE
from the cytoplasm to the nucleus [52]. Furthermore, NE
and MPO have both been observed to decorate the DNA
backbone of NET fibers [2].
Toll-like receptor 4 (TLR4), a receptor triggered by
microbial components mostly expressed on surveilling
immune cells including the neutrophil cell membrane, is
capable of stimulating NETosis via a protein called high
mobility group box 1 (HMGB1) both in vitro and in vivo
in mice. Tadie et al. [33] incubated wild type and TLR4-
deficient mouse neutrophils with HMGB1 and discov-
ered that TLR4-deficient neutrophils released signifi-
cantly less DNA and citrullinated histone 3 (citH3) than
wild type neutrophils. Furthermore, an NADPH oxidase
inhibitor was sufficient to prevent NETosis via PMA
stimulation, but did not reduce NETosis via HMGB1, sug-
gesting that HMGB1 mediates NETosis via a ROS-
independent pathway. Additionally, HMGB1 can also bind
to LPS, creating a synergistic effect promoting NETosis.
The authors found that pretreating mice with both LPS
and HMGB1 increased in vitro NETosis of neutrophils
harvested upon sacrifice when compared to LPS alone.
Upon treatment with LPS and HMGB1 antibodies, NETo-
sis was diminished. Interestingly, HMGB1 is overex-
pressed in several cancers, including the human breast
cancer cell line MCF-7, in which its silencing provoked
significantly higher levels of tumor cell apoptosis and
lower levels of migration and invasion in in vitro assays
[30]. To what extent these anti-tumoral effects occur due
to the disruption of HMGB1-induced NETosis merits fur-
ther investigation.
The receptor for advanced glycation end products
(RAGE) is another damage-associated molecular pattern
(DAMP) receptor that plays a critical role in the patho-
genesis of breast cancer [53] and has also been implicated
in NET formation [54]. Neutrophils collected from RAGE
null mice have diminished potential for NETosis as well as
reduced intra-tumoral and circulating NET biomarkers.
RAGE has been implicated as a key inducer of autophagy
[55], a cell survival mechanism which has also been associ-
ated with NET formation [56, 57]. Neutrophils undergo-
ing NET formation show upregulated autophagy [54, 58].
Furthermore, pharmacologic inhibition of autophagy pre-
vents NETs from forming [59]. While the precise mechan-
ism for autophagy-induced NET formation remains
unclear, this is an area of active study.
Neutrophil maturity may also affect capacity for NETosis.
Terminally differentiated neutrophils may undergo NETo-
sis as a result of the reactivation of cyclin-dependent kinase
6; knockout or inhibition of cyclin-dependent kinase 6
produces neutrophils with a reduced capacity for NETosis
[60]. Additionally, granular content may differ between ma-
ture and immature neutrophils, as neutrophils derived from
acute myeloid leukemia patients, which contain markers
associated with neutrophil immaturity, show a reduced cap-
acity for NET formation when challenged with PMA [61].
Mackey et al.’s [62] recent review details the role of neutro-
phil maturity in the context of cancer in greater detail.
Figure 1 illustrates the role of ROS, neutrophil granule
enzymes MPO and NE, citH3, and neutrophil surface re-
ceptors in promoting tumor-derived NETosis. The follow-
ing sections will highlight the key cellular interactions
between neutrophils, tumor cells, endothelial cells, and
platelets to enable NET release, which are also displayed
in Fig. 1.
Tumor cells
Cancer cells prime neutrophils towards a pro-NETotic
phenotype via the expression and release of various pro-
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NETotic factors such as granulocyte-colony-stimulating
factor (G-CSF) and interleukin-8 (IL-8). Tumor cells have
been observed to act as a source of overexpressed G-CSF
in both murine and human tumors, which activates
neutrophils via binding to the G-CSF receptor on the cell
surface [63–65]. The normal function of G-CSF is to regu-
late leukocyte differentiation, maturation, survival, and
proliferation, as well as facilitate their translocation from
the bone marrow to the bloodstream. Overexpression of
G-CSF in cancer, however, can result in an overabundance
of neutrophils in the blood, ROS generation in neutro-
phils, and subsequent NETosis [19, 36]. Cedervall et al.
[37] have shown that inhibition of G-CSF function in the
MMTV-PyMT transgenic mouse mammary carcinoma
model reduced NETosis and improved peripheral blood
flow. In this study, MMTV-PyMT mice were injected
daily with an anti-G-CSF antibody. After 7 days of treat-
ment, the perfused vessel area within renal tissue was
measured by perfusing the mice with FITC conjugated
lectin before sacrifice and cryosectioning. Mice that re-
ceived anti-G-CSF treatment exhibited significantly in-
creased fluorescent perfusion due to the reduced NET
formation. Ultimately, increased G-CSF expression results
in enhanced metastatic potential for a variety of cancers,
including breast cancer, by activating neutrophils in the
pre-metastatic niche [65, 66].
Fig. 1 Multicellular interactions between neutrophils, tumor cells, platelets and endothelial cells result in NETosis. Shapes are color coded by their
cell or granule of origin: neutrophil nucleus and NETs (dark blue), tumor (green), platelet (lavender), and endothelium (red). (a) The primary tumor
site releases extracellular vesicles (EVs), various ROS generating proinflammatory factors (indicated by “ROS”), and specific pro-NETotic factors into
the circulation. (b) Tissue factor (TF) released from tumor cells activates platelets, provoking the release of HMGB1 and further ROS generation.
Compounding this, tumor released proinflammatory factors may provoke the endothelium as well, dependent on tumor phenotype. (c) Factors
released from the tumor, activated platelets, and activated endothelium bind to their respective receptors on the neutrophil, causing NET release.
Activated platelets can also directly bind to the neutrophil surface through P-selectin (P-SEL)/P-selectin glycoprotein ligand 1 (PSGL-1) interactions
to generate NETosis. Furthermore, tumor-derived EVs may also promote NET release through neutrophil phagocytosis of the tumor membrane
fragments and encapsulated factors. The neutrophil flattens and adheres to the endothelium during this process. (d) Released NETs are decorated
with citH3, NE, and MPO and further activate and entrap platelets, leading to the potential for venous thromboembolism. NETs may also capture
circulating tumor cells, promoting the formation of metastases. (e) NETs damage endothelial cells via proteolytic components such as NE and
MPO, causing the release of inflammatory factors, including IL-8, which can further promote NET release and neutrophil recruitment. Arrested
tumor cells further damage endothelial cells as they extravasate. The now highly inflammatory, crowded environment forms the
pre-metastatic niche.
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Neutrophils are chemotactically attracted to tumor cells
through secretion of IL-8 (also known as CXCL8). It
should be noted that human IL-8 does not have a direct
counterpart in mice. IL-8 binds to G-protein coupled re-
ceptors, CXCR1 and CXCR2, which are expressed by neu-
trophils [67]. IL-8 plays an important role in recruiting
neutrophils to sites of inflammation; as such, women with
breast cancer have higher serum levels of IL-8 compared
to healthy patients. Additionally, IL-8 levels strongly cor-
relate with disease progression [68]. In infectious disease,
recruitment towards inflammation may be beneficial, as
Xu et al. [69] have shown that reduced CXCR1 and
CXCR2 expression on neutrophils correlated with nega-
tive clinical outcomes in hepatitis B due to insufficient
neutrophil recruitment. Other studies have confirmed that
inhibition of IL-8 receptors prevents human neutrophil
chemotaxis in vitro [70]. IL-8 production in multiple can-
cer types, including breast cancer, has also been associated
with increased metastatic potential [35]. IL-8 is capable of
stimulating NETosis in human neutrophils in vitro, and
the addition of IL-8 antibodies abolishes this effect [5, 34].
In mice, CXCL1 (KC), CXCL2 (MIP-2), and CXCL5 and 6
(LIX) serve as functional homologs of IL-8 promoting
murine neutrophil chemotaxis; KC and MIP-2 bind with
CXCR2. While the roles of MIP-2 and LIX in NETosis are
unclear, KC has been shown to promote NETosis in mur-
ine sepsis models [71, 72].
Finally, while PAD4 is localized within the nucleus,
cytoplasm, and secretory granules of neutrophils, it has
also been shown to be expressed in multiple tumor cell
lines. Chang et al. [40] showed that breast tumors in
particular had the greatest PAD4 expression in a variety
of human malignancies, including lung adenocarcin-
omas, colorectal adenocarcinomas, renal cancer cells,
and others; additionally, elevated levels of PAD4 were
detected in patient plasma and associated with the pres-
ence of other tumor biomarkers. The mechanism con-
cerning how PAD4 is exported from tumor cells and
whether extracellular PAD4 can stimulate NETosis has
not been previously studied.
Endothelial cells
In addition to being secreted by tumor cells, IL-8 is also
known to be produced via endothelial cell (EC) activa-
tion [73]. EC activation occurs when the vasculature is
exposed to oxidative stress via injury, inflammation,
chemotherapy, or ionizing radiation [74]. Activated ECs
release inflammatory cytokines and growth factors and
also express several adhesion molecules on their surface
such as P-selectin, E-selectin, and ICAM-1 to facilitate
neutrophil rolling, adhesion, and transmigration to the
inflamed site [75]. Gupta et al. [34] investigated the role
of ECs in promoting NETosis and found that activated
ECs co-cultured with neutrophils in vitro resulted in
NET formation that is partially mediated by IL-8. Re-
leased NETs exposed to the surface of ECs for prolonged
time periods (18 h of neutrophil-EC co-culture) resulted
in eventual EC injury and death, which could be inhib-
ited through NET dissolution by a DNA-degrading en-
zyme, DNase I. NET-induced EC injury and death has
also been observed in vivo, though this has been demon-
strated indirectly. Schreiber et al. [76] found that DNase
I treatment reduced NET formation and protected mice
from blood vessel inflammation, known as vasculitis.
Additionally, Knight et al. [77] showed that PAD4 inhib-
ition via daily injections of Cl-amidine was effective in
reducing NETosis in mice, as well as preventing further
vascular damage and atherosclerosis. Little research has
been done to elucidate the link between NETosis and
cancer-induced endothelial damage. However, tumor
cells themselves can contribute to EC inflammation,
which can enhance the potential to induce NETosis by
further increasing EC damage [34, 78]. The link between
cancer-associated EC activation and NETosis may be
worth further investigation; however, since many of the
same stimuli provoke both neutrophil and EC response,
establishing causality may be difficult.
Platelets
Activated platelets also stimulate NETosis, which sets up
a positive feedback loop, as released NETs are known to
strongly promote a prothrombotic state that further en-
hances platelet activation [79]. Much like endothelial
cells, platelets must undergo activation prior to stimulat-
ing NETosis [25, 31]. Many tumor cell lines including
certain breast cancers have been shown to overexpress
and release tissue factor (TF) [44], which is a well-
established platelet activator. TF levels have been shown
to correlate with mortality in breast cancer patients [80].
However, the use of TF as a biomarker for specifically
defining VTE risk has been demonstrated for some can-
cers yet remains inconclusive for others [81]. Neverthe-
less, Razak et al. [82] suggest that cancer may activate
platelets through uptake of small tumor-derived extra-
cellular vesicles, which often contain TF. Neutrophils
also contain tissue factor, which is released from NETs
to further promote a positive feedback loop by stimulat-
ing platelets [42, 43]. Further investigation into the
mechanisms of TF-mediated increases in mortality inde-
pendent of VTE risk would be interesting.
Post activation, platelets can stimulate NET release
through direct adhesive interactions with neutrophils
[41, 83]; upon activation, platelets rapidly translocate an
adhesion molecule known as P-selectin to their surface
[84], which can bind to the neutrophil surface receptor
P-selectin glycoprotein ligand-1 (PSGL-1) to promote
neutrophil-platelet adhesion [85], neutrophil activation
[86], and subsequent NET release. Etulain et al. [41]
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show thrombin activated platelets elicit NETosis both
in vitro and in vivo in murine neutrophils, and NET for-
mation does not occur when either P-selectin or PSGL-1
inhibitory antibodies are introduced. NETosis was also
abolished in P-selectin knockout mice. Interestingly, sol-
ubilized P-selectin alone was also observed to stimulate
NETosis, but to a lesser extent than activated platelets
[41]. This potential NETosis pathway could also be rele-
vant in cancer where high levels of soluble P-selectin
found in patient blood plasma have been linked to
higher rates of VTE [87].
Both TLR4 and HMGB1 are also expressed by platelets
and have been shown to be another means of platelet-
stimulated NETosis relevant to cancer [25, 31]. In septic
mice, Clark et al. [31] were the first to show that LPS binds
to TLR4 to enable platelet activation, neutrophil-platelet ag-
gregate formation, subsequent neutrophil activation, and
NET release. Platelet HMGB1 can cause NETosis through
neutrophil TLR4 activation, or alternatively can bind to the
neutrophil RAGE receptor to stimulate NETosis. Maugeri
et al. [25] found that when human platelets were activated
with a variety of factors, including thrombin or collagen,
they were able to stimulate NETosis via HMGB1. NETosis
was abolished when RAGE was blocked via antibodies. The
authors also show that HMGB1 is no longer present in
platelets post activation, indicating that it is released rather
than translocated to the membrane. It is conceivable that
platelets may serve as an intermediary between tumor cells
to influence neutrophils and promote NETosis via the re-
lease of platelet-activating soluble factors, such as HMGB1.
Extracellular vesicles
Though initially thought to solely be biomarkers, current
literature suggests that extracellular vesicles (EVs) actively
contribute to angiogenesis, metastasis, and coagulation
[21, 88]. The role of EVs in promoting NETosis in the
context of cancer is only just being explored. Broadly, EVs
are formed when a piece of membrane sheds from the
parent cell to form membrane-enclosed particles, the con-
tents of which depend on the phenotype of the parent cell.
Ultimately, any cytoplasmic material in the parent cell can
be present in its EVs; EVs are extremely heterogenous and
can also form from the Golgi or endosomal membrane
[89]. Though EVs can be further subcategorized based on
size or origin, the term “extracellular vesicle” refers to any
particle 50–1500 nm in diameter [90]. EV release often oc-
curs as a stress response. Consequently, EVs are more
highly concentrated in cancer patients than in healthy in-
dividuals. Elevated EV content in breast cancer patient
blood serves as an indicator of more advanced disease
stage and is associated with worse therapeutic success and
lower 3-year survival rates [91]. While the cargo, RNA,
DNA, and membrane proteins present in EVs from cancer
patients have not yet been fully characterized, cancer-
derived EVs have been associated with high expression of
pro-NETotic and pro-tumoral factors such as interleukins
and G-CSF [92–94]. We will discuss EVs derived from
tumor-burdened organisms and from tumor cell culture.
As tumor-derived EVs are just recently being observed to
modulate neutrophil behavior, including NETosis, it is not
surprising that the growth factors and cytokines these EVs
carry can further contribute to the inflammatory micro-
environment of a nascent pre-metastatic niche.
Leal et al.’s recent study [21] shows that EVs derived
from cultured 4T1 mouse breast cancer cells stimulated
NETosis in vitro in neutrophils primed with G-CSF.
BALB/c mice with orthotopic mammary 4T1 tumors
were shown to have significantly more EVs present in
blood plasma compared to control mice without tumors.
The evaluated population contained particles approxi-
mately 80–110 nm in diameter. Mice containing 4T1
tumors exhibited more rapid coagulation in venous and
arterial injury models compared to control mice. The
enhanced prothrombotic state of 4T1 mice could be
inhibited through use of DNase I, suggesting a role of
NETs in platelet activation. Notably, healthy mice injected
with G-CSF and culture-derived 4T1 EVs experienced
more rapid coagulation induced via photochemical vascu-
lar injury than did healthy mice given G-CSF only. NETs
were observed (though not quantified) within these
thrombi, suggesting that EVs could lead to NET release
and subsequent coagulation in vivo. However, the use of
exclusively tumor-derived EVs is limiting, as it does not
account for the release and content of EVs derived from
other blood cells in tumor-burdened organisms. EVs re-
leased from other cells such as platelets, endothelial cells,
and macrophages may also be tumor mediated, since EVs
facilitate intracellular communication between tumors
and other cells [92]. Despite this, to our knowledge, Leal
et al.’s study has been the only published work to examine
the direct stimulatory effect of tumor-derived EVs on
NETosis.
Similarly, the specific mechanisms of interaction between
neutrophils and EVs leading to NETosis are largely un-
known. However, Headley et al. [95] utilized fluorescence
intravital microscopy of lungs in live mice to show that B16
melanoma cells, injected intravascularly via the tail vein, at-
tached to the pulmonary endothelium and subsequently re-
leased large membrane bound particles of around 5 μm.
Fascinatingly, the authors observed that neutrophils and
other immune cells had phagocytosed fragments of these
tumor-derived microparticles in vivo. As such, it is not un-
reasonable to conclude that ingested tumor material may
have a stimulatory effect on immune cells. These implica-
tions are supported by evidence showing that neutrophils
uptake tumor-derived DNA delivered via EVs, which may
contain pro-NETotic cargo. In fact, Chennakrishnaiah et al.
[96] recently showed that white blood cells contained the
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highest concentration of human epidermal growth factor
receptor 2 (HER2) oncogenic DNA in SCID mice bearing
BT474 breast tumor xenografts (a HER2-positive human
breast carcinoma) compared to other blood components,
including plasma, suggesting that neutrophils may be espe-
cially prone to stimulation from tumor-derived EVs. A par-
allel experiment examining the oncogenic DNA content of
a different human breast cancer oncogene, HRAS, within
the white blood cells of RAS-3 burdened SCID mice
showed that neutrophils were the major contributor to this
uptake and that neutrophil depletion resulted in far higher
plasma oncogenic DNA concentration. Finally, RAS-3-
derived exosomes were shown to trigger a significant in-
crease in endogenous expression of IL-8 in vitro in human
neutrophil-like cells, or HL60. These findings provide inter-
esting insights into the NETosis stimulation exhibited by
tumor-derived EVs. NETosis may be both directly induced
via stimulants expressed by the tumor cell and contained
within EVs, and EVs may induce neutrophils to produce
their own NETosis stimulants. However, our understanding
of the role of EVs in causing NETosis remains limited.
Though proteomic analysis has been performed on a var-
iety of tumor-derived EV populations, the content of
known NETotic agents has not been examined. Addition-
ally, whether neutrophils internalize EVs predominantly
through phagocytosis or receptor mediated endocytosis is
also unknown.
Impact of NETosis on VTE and metastasis
Figure 2 shows the integration of multiple NET stimuli
and the downstream effects of NET release including en-
hanced VTE and metastasis. NETs have been identified
as a prognostic indicator of VTE and are at least partially
responsible for the hypercoagulable state observed in
cancer patients. It is estimated that women with breast
cancer are three to four times more likely to develop
VTE compared to age-matched women without breast
cancer [97]. VTE occurring in breast cancer patients has
also been linked to reduced patient survival and tumor
recurrence. Mauracher et al. [26] recently observed that
high plasma levels of NET marker, citH3, were predict-
ive of an increased risk of VTE for 2 years post diagnosis
or relapse in a cohort of nearly a thousand cancer pa-
tients; interestingly, levels of circulating DNA were only
predictive of increased VTE risk during the first 3 to 6
months. Of the tumor sites examined, brain, lung, and
breast showed the highest frequency of patients whose
sera contained elevated citH3 levels. For these patients,
the 2-year risk of VTE was 14.5%, as opposed to 8.5%
for patients lacking elevated citH3. An increase in citH3
of only 100 ng/mL was found to translate to a 13%
higher risk of VTE, suggesting that even mild NETosis
may severely impact prognosis. The hypercoagulability
characteristic of cancer patients has been shown to be
largely NETosis dependent in breast cancer models [21].
Demers et al. [19] showed that G-CSF seems to further
drive the prothrombotic state by priming neutrophils for
NETosis in a 4T1 mammary carcinoma mouse model.
Tumor-bearing mice experienced a significant decrease
in both platelet and neutrophil counts consistent with
thrombus formation and had reduced tail bleed times. In
tumor-burdened mice, the highest levels of citH3 were
present in the later stages of disease.
It has also been suggested that NETs promote the forma-
tion of the pre-metastatic niche, at least partly by entrap-
ping circulating tumor cells in their web-like structure,
providing a site from which these cells may then extrava-
sate. Cools-Lartigue et al. [10] showed via intravital micros-
copy that NETs were able to arrest circulating tumor cells
in the pulmonary and hepatic microvasculature. A septic
Fig. 2 Flowchart illustrating the causes of NET formation and the means by which NETosis leads to disease progression downstream
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state was induced in C57BL/6 J mice prior to intrasple-
nic injection of H59 Lewis lung carcinoma cells. Micro-
metastases were observed within 48 h, with both NE
inhibitor and DNase I treatment abolishing this effect;
non-septic mice showed few micrometastases, suggest-
ing that pro-NETotic stimuli are required to enhance
NET-mediated metastasis. Park et al.’s [27] recent study
shows that 4T1 breast cancer cells injected into the tail
vein of LysM-EGFP mice were found within lungs and
caused NET formation; immunofluorescence staining of
lung tissue sections showed via DNA and NE fluorescence
that tumor cells were sufficient to provoke increased rates
of lytic NETosis for up to 4 days post injection. DNase I-
coated nanoparticle treatment reduced tumor invasion
in vitro and the number and size of lung metastases
in vivo.
Interestingly, surgical resection aimed at decreasing
tumor burden can actually promote metastasis through
neutrophil activation and subsequent NET formation. In-
creased NETosis in patients undergoing liver resection
due to metastatic colorectal cancer correlates to markedly
lower cancer-free survival [14]. This effect of increased
metastasis following surgical stress was reproduced in
mouse models and was abolished by DNase I treatment or
inhibiting PAD4 to dissociate NETs or prevent their re-
lease, respectively. Neutrophil HMGB1 release occurred
concurrently with pro-NETotic stimulation, and HMGB1
was also associated with NETs. This represents a means
by which NETs may directly activate platelets and other
neutrophils, eventually forming a thrombus. Circulating
tumor cells (the presence of which may be increased by
surgical disruption of the primary tumor) could then be
captured due to partial vessel blockage and the coagulat-
ing microenvironment around the NET. Simultaneously,
the capacity of NETs to damage endothelial cells likely en-
ables arrested tumor cells to adhere to the activated endo-
thelium, eventually extravasating and establishing a new
metastatic site. Interestingly, NETs have also been shown
to activate dormant single breast tumor cells in mouse
lungs, which can then lead to metastasis development.
Cancer cell activation from dormancy is thought to occur
via the remodeling of extracellular matrix due to NET-
associated NE and is further facilitated by G-CSF [13].
It is reasonable to conclude that tumor-driven NETo-
sis alone, even without surgical stress or major infection,
can also serve to drive metastasis. Pro-NETotic factors
are known to be overexpressed by many tumor lines,
and multiple murine breast cancer models have been
shown to promote NETosis. However, much remains
unclear about the specific mechanism in which cancer
promotes metastasis through NET formation. It is cur-
rently unknown whether NETs predominantly contrib-
ute to metastatic establishment via endothelial damage
or direct sequestration of tumor cells. Additionally, little
is known about the timeline of NET generation. It is
possible that the primary tumor site must reach enough
development to elicit NETosis, which then promotes the
establishment of metastases. Alternatively, pioneering
tumor cells may secrete pro-NETotic factors which then
provoke a NET-induced inflammatory state from sur-
rounding neutrophils, favoring tumor cell invasion and
further sequestration of circulating tumor cells.
NETs as biomarkers and clinical targets
The ability to detect NETs would likely be of significant
prognostic use in differentiating patients at higher risk of
metastatic progression or VTE, thereby enabling clinicians
to better personalize treatment regimens. To develop a
clinical screening tool for NETs, a standardized definition
of “normal” levels of NETosis would need to be estab-
lished and has not yet been presented in the literature.
The simplest means of in vivo NET detection involves
measurement of NET-associated products in the blood
such as circulating cell-free DNA, citH3, NE, and MPO.
For example, free circulating DNA has been quantified in
both colorectal and breast cancer patient serum samples
via a simple nucleic acid staining assay [98, 99]. However,
even though circulating DNA is known to correlate with
breast tumor size and malignancy [100], it lacks specificity
in measuring NETosis. An increased amount of DNA in
cancer patient serum can also be attributable to other
factors such as apoptotic and necrotic cells. Measuring
circulating MPO/DNA conjugates is more specific for
NET formation than evaluation of cell-free DNA alone
[101]. Citrullinated histone H3 (citH3) is formed as a re-
sult of PAD4-mediated citrullination during NET forma-
tion and represents the most specific biomarker for
circulating NETs [26]. In addition, citH3 may be of prog-
nostic significance, as Thålin et al. [102] observed that
high plasma content of citH3 was a significant indicator of
short-term mortality in late-stage cancer patients, even
when compared to severely ill patients without cancer.
Additionally, IL-8 levels were found to correlate with
levels of citH3. Since higher levels of IL-8 would result in
increased neutrophil recruitment, it would be reasonable
to conclude that this higher density of neutrophils would
subsequently lead to increased NETosis. Despite this,
other markers associated with NETs including NE and
MPO were not found to differ significantly between se-
verely ill patients with and without malignancy; however,
these neutrophil-derived enzymes can be independently
released during neutrophil degranulation in the absence of
NET formation, and therefore may not be reliable NET-
specific biomarkers. Indeed, citH3 seems to be the most
consistent indicator of NETosis. While levels of other
markers may provide useful insight into neutrophil behav-
ior, citH3 is highly specific to NETosis and thus would be
valuable in understanding variances between other NET-
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associated biomarkers. CitH3 levels are also predictive of
VTE risk in newly diagnosed patients, further supporting
its diagnostic utility [26].
The development of clinical therapies specifically target-
ing NETs in cancer is in its infancy. Inhibition of NETosis
has been achieved through several means, though these
vary in their potential for clinical therapies. For instance,
DNase I treatment degrades NETs and results in a loss of
the web-like structure and a reduction in the capacity to
promote metastasis in several studies [10, 14, 21, 34]. In
addition, DNase I has been shown to decrease tumor vol-
ume in rats when injected intramuscularly or intraperitone-
ally in conjunction with other proteases (papain, trypsin,
and chymotrypsin) [103]; however, it is not known whether
these effects are due primarily to NET inhibition. Currently,
DNase I is used clinically in the treatment of cystic fibrosis,
as it decreases the NETosis-mediated buildup of mucous
viscosity, resulting in improved lung function [6]. However,
in this context, DNase I is delivered via nebulizer, which
would likely be ineffectual in most cancer treatments,
though it would be fascinating to observe whether nebu-
lized DNase I would have a preventative effect on lung me-
tastasis. Additionally, DNase I injection may have off-target
effects, including compromising the immunoprotective
function of NETs.
Inhibition of components integral to NETosis, such as
NE or PAD4, would likely have similar off-target effects
due to their involvement in other key pathways, potentially
disrupting normal neutrophil function. Small molecule
inhibitors of PAD4 for NET inhibition are under active
investigation and include Cl-amidine and F-amidine, irre-
versible inhibitors that inactivate calcium-bound PAD4
[104]. However, these lack specificity and interact with
other PAD-family enzymes. Recently, Lewis et al. [105]
synthesized two reversible inhibitors which overcome this
hurdle, GSK199 and GSK484, both of which exhibit high
specificity for PAD4 and inhibit NETosis in both mouse
and human neutrophils. GSK484 was recently shown to
prevent tumor-associated renal dysfunction in mice, which
was determined to be NET-mediated; the inhibitory effects
of GSK484 were as effective as DNase I [106]. Additionally,
a recent study by Yazdani et al. [107] indicates that PAD4-
knockout mice challenged with subcutaneous tumor injec-
tion of colorectal and hepatocellular carcinoma tumor cells
experienced slower tumor growth and smaller metastases
similar to mice treated with daily DNase I injection.
NETs were not observable in excised tumor tissue in
PAD4-knockout mice. Finally, the authors showed that
NETosis at the primary tumor site may contribute to
tumor cell survival through enhanced mitochondrial
biogenesis. This data further supports the need to de-
velop NET-targeting treatments, as these would be of
great therapeutic benefit in both the context of the pri-
mary tumor site and the pre-metastatic niche.
Efforts targeting cell adhesive molecules, such as P-
selectin, could also prove problematic. Though successful
results of a stage II clinical trial for the use of the P-
selectin inhibitor crizanlizumab in sickle cell anemia to
prevent vaso-occlusion were recently published [108], it
would be reasonable to conclude that such a therapy may
interfere with leukocyte function. Though P-selectin and
PSGL-1 antibodies have been shown to inhibit NETosis in
mice [41], the disruption of leukocyte adhesion molecule
binding capacity could decrease neutrophil recruitment in
response to infection in cancer patients already suffering
from an immunocompromised state. Off-target effects
could potentially be mitigated via the development of new,
more specific delivery vehicles, such as functionalized, tar-
geted nanoparticles.
Alternatively, the adaptation of FDA-approved drugs
could facilitate the development of effective anti-NET
treatments. For instance, the inhibitory effect of aspirin on
NETs has yielded some promising results in animal
models. Lapponi et al. [109] showed that aspirin prevented
NET-induced injury of the lung endothelium by inhibiting
platelet activation and subsequent NET formation in mice.
The inhibitory effect of aspirin on NF-κB, an inflamma-
tory transcriptional regulator that plays a role in some
pathways promoting NETosis, was also demonstrated.
The authors found that aspirin treatment effectively inhib-
ited NETs in human neutrophils in vitro and resulted in
higher bacteria counts in infection-burdened mice in vivo,
suggesting a loss of normal NET functionality. There is
evidence to support the use of aspirin in clinical treat-
ment. In one meta-analysis, patients using aspirin daily
had significantly reduced mortality and risk of distant me-
tastases for adenocarcinomas. Interestingly, this effect did
not appear to be dose dependent [110]. Aspirin has also
been shown to be effective in reducing metastasis in pa-
tients suffering from breast cancer specifically [111].
Another FDA-approved drug, hydroxychloroquine, origin-
ally used to treat malaria, has been shown to inhibit NETosis
[17, 54, 112]. While the mechanism behind NET inhibition
by hydroxychloroquine is unclear, it may be related to au-
tophagy inhibition [113]. However, a phase II clinical study
on patients with advanced pancreatic cancer produced little
clinical effect. The authors do suggest, however, that combin-
ation therapy may prove more effective [114]. Furthermore,
use of hydroxychloroquine as a neoadjuvant treatment in
earlier stage disease holds significant promise [115]. Remark-
ably, and perhaps not coincidentally, hydroxychloroquine
also inhibits leukocyte phagocytosis [116]. Thus, it may be
possible that hydroxychloroquine could inhibit neutrophil
uptake of tumor-derived EVs, thus reducing NETosis. How-
ever, the precise mechanism by which this uptake occurs is
unknown, as are the mechanisms behind tumor-derived EV
stimulated NETosis. Due to the associated complications of
NETs including increased VTE risk and metastasis, which
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are both negatively associated with breast cancer patient out-
come, it is crucial for future research efforts to focus on fur-
ther investigation of new specific targets to prevent NET
formation.
Conclusion
Evidence is mounting that NETs play a significant detri-
mental role in the inflammatory state of cancer. We have
presented several classical NETotic stimuli, as well as stim-
uli that have been implicitly or explicitly demonstrated to
induce NETosis specifically within the context of cancer,
though the mechanisms by which such stimuli occur are
not yet entirely defined. We have also discussed the nega-
tive outcomes NETs promote and have highlighted poten-
tial NET-specific targets to investigate and utilize to
develop therapies for clinical translation. The next vital step
will be untangling the web of crosstalk between neutrophils,
tumor cells, endothelial cells, platelets, and extracellular
vesicles, and eventually the influence of other components
of the innate and adaptive immune systems on cancer pro-
gression. Better understanding of these processes will en-
able the development of precise NET-targeted therapies
and diagnostic tools, potentially allowing the identification
of tumors with the potential for metastasis, earlier diagno-
sis, and more personalized and effective treatments for
breast cancer patients.
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